Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
$1.12
+8.7%		$1.38
$0.55
▼
$4.43
$10.15M0.31371,589 shs545,557 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.31
-0.8%		$1.30
$0.85
▼
$2.23
$33.44M1.79528,014 shs150,061 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
+8.74%-13.18%-16.42%-8.94%-27.27%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-0.76%-9.03%+24.76%-25.99%-2.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
$1.12
+8.7%		$1.38
$0.55
▼
$4.43
$10.15M0.31371,589 shs545,557 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.31
-0.8%		$1.30
$0.85
▼
$2.23
$33.44M1.79528,014 shs150,061 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
+8.74%-13.18%-16.42%-8.94%-27.27%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-0.76%-9.03%+24.76%-25.99%-2.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
1.50
ReduceN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
3.00
Buy$6.00358.02% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
$659.94K15.38N/AN/A$2.61 per share0.43
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/A$0.66 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-$8.29M-$0.40N/AN/AN/AN/A-87.90%-78.69%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
N/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
0.44
0.52
0.43
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/A
3.44
2.47

Institutional Ownership

CompanyInstitutional Ownership
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
N/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
10.30%

Insider Ownership

CompanyInsider Ownership
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
18.20%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
309.06 million7.41 millionNot Optionable
NanoViricides, Inc. stock logo
NNVC
NanoViricides
725.53 million14.92 millionOptionable

Recent News About These Companies

Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
October 13 at 8:45 AM  |  accessnewswire.comA
NanoViricides (NYSE:NNVC) Shares Down 3.4% - Time to Sell?
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31094303
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
October 6, 2026  |  accessnewswire.comA
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over ...
October 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NNVC/pressreleases/4961335/nanoviricides-provides-additional-details-on-the-phase-ii-clinical-trial-of-nv-387-oral-gummies-as-a-treatment-for-ebola-as-the-outbreak-continues-to-expand-and-has-taken-over-4000-lives/
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
October 5, 2026  |  accessnewswire.comA
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week, Says NanoViricides
September 29, 2026  |  marketscreener.comM
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
September 29, 2026  |  accessnewswire.comA
NanoViricides: Fiscal Q4 Earnings Snapshot
September 28, 2026  |  khou.comK
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
September 28, 2026  |  accessnewswire.comA
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
September 23, 2026  |  accessnewswire.comA
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48 ...
September 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/clinical-trial-oral-drug-nv-132500733.html
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in 
DR Congo with 48% Crude Fatality Rate, Says NanoViricides
September 15, 2026  |  accessnewswire.comA
Ebola Clinical Trial for Oral Drug NV-387 Registered in DRC
September 8, 2026  |  desmoinesregister.comD
Ebola Oral Drug Trial NV-387 Registered in DRC for Outbreak
September 8, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/42555/ebola-oral-drug-trial-nv-387-registered-in-drc-for-outbreak/
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand ...
September 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/clinical-trial-oral-drug-treat-123000295.html
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
September 8, 2026  |  accessnewswire.comA
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 ...
August 31, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/41622/while-measles-cases-continue-to-increase-in-the-usa-and-globally-nanoviricides-is-getting-ready-for-clinical-trials-of-its-revolutionary-broad-spectrum-drug-candidate-nv-387-as-a-treatment-for-measle/
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
August 31, 2026  |  accessnewswire.comA
NanoViricides Inc
August 19, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/nnvc-nanoviricides-inc/vitals
NanoViricides: The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
August 19, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69342159-nanoviricides-the-phase-ii-clinical-trial-of-nv-387-oral-gummies-as-a-treatment-for-ebola-in-dr-congo-to-fight-the-current-largest-ever-and-expanding-200.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Mainz Biomed stock logo

Mainz Biomed NASDAQ:MYNZ

$1.12 +0.09 (+8.74%)
As of 10/13/2026

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

NanoViricides stock logo

NanoViricides NYSE:NNVC

$1.31 -0.01 (-0.76%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$1.29 -0.02 (-1.45%)
As of 07:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas